recent Advances in Mechanisms and Treatments of Airway remodeling in Asthma: A Message from the Bench Side to the Clinic = recent Advances in Mechanisms and Treatments of Airway remodeling in Asthma: A Message from the Bench Side to the Clinic

다국어 초록 (Multilingual Abstract)

Airway remodeling in asthma is a result of persistent inflammation and epithelial damage in response to repetitive injury. Recent studies have identified several important mediators associated with airway remodeling in asthma, including transforming growth factor-β, interleukin (IL)-5, basic fibroblast growth factor, vascular endothelial growth factor, LIGHT, tumor necrosis factor (TNF)-α, thymic stromal lymphopoietin, IL-33, and IL-25. In addition, the epithelium mesenchymal transformation (EMT) induced by environmental factors may play an important role in initiating this process. Diagnostic methods using sputum and blood biomarkers as well as radiological interventions have been developed to distinguish between asthma sub-phenotypes. Human clinical trials have been conducted to evaluate biological therapies that target individual inflammatory cells or mediators including anti IgE, anti IL-5, and anti TNF-α. Furthermore, new drugs such as c-kit/platelet-derived growth factor receptor kinase inhibitors, endothelin-1 receptor antagonists, calcium channel inhibitors, and HMG-CoA reductase inhibitors have been developed to treat asthma-related symptoms. In addition to targeting specific inflammatory cells or mediators, preventing the initiation of EMT may be important for targeted treatment. Interestingly, bronchial thermoplasty reduces smooth muscle mass in patients with severe asthma and improves asthma-specific quality of life, particularly by reducing severe exacerbation and healthcare use. A wide range of different therapeutic approaches has been developed to address the immunological processes of asthma and to treat this complex chronic illness. An important future direction may be to investigate the role of mediators involved in the development of airway remodeling to enhance asthma therapy.

참고문헌 (Reference)

• 1 Le AV, "nhibition of allergen-induced airway remodeling in Smad 3-deficient mice" 178 : 7310-7316, 2007
• 2 Wang YH, "hymic stromal lymphopoietin, OX40-ligand, and interleukin-25 in allergic responses" 39 : 798-806, 2009
• 3 Luzina IG, "ccurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients" 48 : 2262-2274, 2003
• 4 Bae YJ, "Vascular endothelial growth factor levels in induced sputum and emphysematous changes in smoking asthmatic patients" 103 : 51-56, 2009
• 5 Lee CG, "Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung" 10 : 1095-1103, 2004
• 6 Kanazawa H, "Up-regulation of thrombin activity induced by vascular endothelial growth factor in asthmatic airways" 132 : 1169-1174, 2007
• 7 Qu Z, "Ultrastructural immunolocalization of basic fibroblast growth factor in mast cell secretory granules: morphological evidence for bfgf release through degranulation" 46 : 1119-1128, 1998
• 8 Bosse Y, "Transforming growth factor-beta1 in asthmatic airway smooth muscle enlargement: is fibroblast growth factor-2 required" 40 : 710-724, 2010
• 9 Redington AE, "Transforming growth factor-beta 1 in asthma: measurement in bronchoalveolar lavage fluid" 156 : 642-647, 1997
• 10 Shan L, "Thymic stromal lymphopoietin receptor-mediated IL-6 and CC/CXC chemokines expression in human airway smooth muscle cells: role of MAPKs (ERK1/2, p38, and JNK) and STAT3 pathways" 184 : 7134-7143, 2010
• 11 Ying S, "Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity" 174 : 8183-8190, 2005
• 12 Zhou B, "Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice" 6 : 1047-1053, 2005
• 13 Soja J, "The use of endobronchial ultrasonography in assessment of bronchial wall remodeling in patients with asthma" 136 : 797-804, 2009
• 14 Mitsunobu F, "The use of computed tomography to assess asthma severity" 5 : 85-90, 2005
• 15 Doherty TA, "The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling" 17 : 596-603, 2011
• 16 Lee YC, "The involvement of matrix metalloproteinase-9 in airway inflammation of patients with acute asthma" 31 : 1623-1630, 2001
• 17 Erin EM, "The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma" 174 : 753-762, 2006
• 18 Jie Z, "The effects of Th2 cytokines on the expression of ADAM33 in allergen-induced chronic airway inflammation" 168 : 289-294, 2009
• 19 Holgate S, "The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation" 115 : 459-465, 2005
• 20 Moussion C, "The IL-1-like cytokine IL- 33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’" 3 : 3331-, 2008
• 21 Strutz F, "TGF-beta 1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2)" 59 : 579-592, 2001
• 22 Corrigan CJ, "T-helper cell type 2 (Th2) memory T cell-potentiating cytokine IL-25 has the potential to promote angiogenesis in asthma" 108 : 1579-1584, 2011
• 23 Dube J, "Synergistic action of endothelin (ET)-1 on the activation of bronchial fibroblast isolated from normal and asthmatic subjects" 81 : 429-437, 2000
• 24 Yanai M, "Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure" 72 : 1016-1023, 1992
• 25 Menzies D, "Simvastatin does not exhibit therapeutic antiinf lammatory effects in asthma" 119 : 328-335, 2007
• 26 Halwani R, "Role of transforming growth factor-β in airway remodeling in asthma" 44 : 127-133, 2011
• 27 Rasmussen F, "Risk factors for airway remodeling in asthma manifested by a low postbronchodilator FEV1/vital capacity ratio: a longitudinal population study from childhood to adulthood" 165 : 1480-1488, 2002
• 28 Cho SH, "Regulation of activin A expression in mast cells and asthma: its effect on the proliferation of human airway smooth muscle cells" 170 : 4045-4052, 2003
• 29 Danek CJ, "Reduction in airway hyperresponsiveness to methacholine by the application of RF energy in dogs" 97 : 1946-1953, 2004
• 30 Lim DH, "Reduced peribronchial fibrosis in allergen-challenged MMP-9-deficient mice" 291 : 265-271, 2006
• 31 Lopez AF, "Recombinant human interleukin 5 is a selective activator of human eosinophil function" 167 : 219-224, 1988
• 32 Jeon SG, "Recombinant basic fibroblast growth factor inhibits the airway hyperresponsiveness, mucus production, and lung inflammation induced by an allergen challenge" MOSBY-ELSEVIER 119 : 831-837, 2007
• 33 Gupta S, "Quantitative analysis of high-resolution computed tomography scans in severe asthma subphenotypes" 65 : 775-781, 2010
• 34 Holgate ST, "Puddicombe SM, Lordan JL. Epithelial-mesenchymal interactions in the pathogenesis of asthma" 105 (105): 193-204, 2000
• 35 Hart TK, "Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma" 130 : 93-100, 2002
• 36 Zhu G, "Polymorphisms in the endothelin-1 (EDN1) are associated with asthma in two populations" 9 : 23-29, 2008
• 37 Broekema M, "Persisting remodeling and less airway wall eosinophil activation in complete remission of asthma" 183 : 310-316, 2011
• 38 Castro M, "Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma" 107 : 65-70, 2011
• 39 Gregory LG, "Overexpression of Smad2 drives house dust mite-mediated airway remodeling and airway hyperresponsiveness via activin and IL-25" 182 : 143-154, 2010
• 40 Zhiguang X, "Over-expression of IL- 33 leads to spontaneous pulmonary inflammation in mIL-33 transgenic mice" 131 : 159-165, 2010
• 41 Hurst SD, "New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25" 169 : 443-453, 2002
• 42 Tateno H, "Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6’-sulfo-sialyl Lewis X as a preferred glycan ligand" 15 : 1125-1135, 2005
• 43 Nair P, "Mepolizumab for prednisone-dependent asthma with sputum eosinophilia" 360 : 985-993, 2009
• 44 Haldar P, "Mepolizumab and exacerbations of refractory eosinophilic asthma" 360 : 973-984, 2009
• 45 Reuter S, "Mast cell-derived tumour necrosis factor is essential for allergic airway disease" 31 : 773-782, 2008
• 46 Nakae S, "Mast cell-derived TNF contributes to airway hyperreactivity, inflammation, and TH2 cytokine production in an asthma model in mice" 120 : 48-55, 2007
• 47 Humbert M, "Masitinib, a c-kit/ PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics" 64 : 1194-1201, 2009
• 48 McMillan SJ, "Manipulation of allergeninduced airway remodeling by treatment with anti-TGF-beta antibody: effect on the Smad signaling pathway" 174 : 5774-5780, 2005
• 49 Thomson NC, "Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial" 11 : 8-, 2011
• 50 Owyang AM, "Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract" 203 : 843-849, 2006
• 51 Angkasekwinai P, "Interleukin 25 promotes the initiation of proallergic type 2 responses" 204 : 1509-1517, 2007
• 52 Jacquet A, "Interactions of airway epithelium with protease allergens in the allergic response" 41 : 305-311, 2011
• 53 Kang JY, "Inhibitory effects of anti-immunoglobulin E antibodies on airway remodeling in a murine model of chronic asthma" 47 : 374-380, 2010
• 54 Cho JY, "Inhibition of airway remodeling in IL-5-deficient mice" 113 : 551-560, 2004
• 55 Berlin AA, "Inhibition of SCF attenuates peribronchial remodeling in chronic cockroach allergeninduced asthma" 86 : 557-565, 2006
• 56 Delimpoura V, "Increased levels of osteopontin in sputum supernatant in severe refractory asthma" 65 : 782-786, 2010
• 57 Foley SC, "Increased expression of ADAM33 and ADAM8 with disease progression in asthma" 119 : 863-871, 2007
• 58 Prefontaine D, "Increased IL-33 expression by epithelial cells in bronchial asthma" 125 : 752-754, 2010
• 59 Broide DH, "Immunologic and inflammatory mechanisms that drive asthma progression to remodeling" 121 : 560-570, 2008
• 60 Asai K, "Imbalance between vascular endothelial growth factor and endostatin levels in induced sputum from asthmatic subjects" 110 : 571-575, 2002
• 61 Smith DE, "IL-33: a tissue derived cytokine pathway involved in allergic inf lammation and asthma" 40 : 200-208, 2010
• 62 Schmitz J, "IL-33, an interleukin-1- like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines" 23 : 479-490, 2005
• 63 Wood IS, "IL-33, a recently identified interleukin- 1 gene family member, is expressed in human adipocytes" 384 : 105-109, 2009
• 64 Rankin AL, "IL-33 induces IL-13- dependent cutaneous fibrosis" 184 : 1526-1535, 2010
• 65 Lloyd CM, "IL-33 family members and asthma - bridging innate and adaptive immune responses" 22 : 800-806, 2010
• 66 Sanada S, "IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system" 117 : 1538-1549, 2007
• 67 Kurowska-Stolarska M, "IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation" 183 : 6469-6477, 2009
• 68 Fort MM, "IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo" 15 : 985-995, 2001
• 69 Costa JJ, "Human eosinophils can express the cytokines tumor necrosis factor-alpha and macrophage inflammatory protein-1 alpha" 91 : 2673-2684, 1993
• 70 Heijink IH, "House dust mite-promoted epithelial-to-mesenchymal transition in human bronchial epithelium" 42 : 69-79, 2010
• 71 Bochner BS, "Glycan array screening reveals a candidate ligand for Siglec-8" 280 : 4307-4312, 2005
• 72 Clauss M, "Functions of the VEGF receptor-1 (FLT-1) in the vasculature" 8 : 241-245, 1998
• 73 Powers CJ, "Fibroblast growth factors, their receptors and signaling" 7 : 165-197, 2000
• 74 Bosse Y, "Fibroblast growth factor 2 and transforming growth factor beta1 synergism in human bronchial smooth muscle cell proliferation" 34 : 746-753, 2006
• 75 Bosse Y, "FGF2 in asthmatic airwaysmooth- muscle-cell hyperplasia" 14 : 3-11, 2008
• 76 Ying S, "Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease" 181 : 2790-2798, 2008
• 77 Berry MA, "Evidence of a role of tumor necrosis factor alpha in refractory asthma" 354 : 697-708, 2006
• 78 Fain SB, "Evaluation of structure-function relationships in asthma using multidetector CT and hyperpolarized He-3 MRI" 15 : 753-762, 2008
• 79 de Lange EE, "Evaluation of asthma with hyperpolarized helium-3 MRI: correlation with clinical severity and spirometry" 130 : 1055-1062, 2006
• 80 김윤근, "Essential role of nitric oxide in VEGF-induced, asthma-like angiogenic, inflammatory, mucus, and physiologic responses in the lung" NATL ACAD SCIENCES 103 (103): 11021-11026, 200607
• 81 Heijink IH, "Epidermal growth factor receptor signalling contributes to house dust mite-induced epithelial barrier dysfunction" 36 : 1016-1026, 2010
• 82 van Rensen EL, "Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment" 64 : 72-80, 2009
• 83 Rothenberg ME, "Eosinophilia" 338 : 1592-1600, 1998
• 84 Borish LC, "Efficacy of soluble IL-4 receptor for the treatment of adults with asthma" 107 : 963-970, 2001
• 85 Holgate ST, "Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial" 37 : 1352-1359, 2011
• 86 Holgate S, "Effects of omalizumab on markers of inflammation in patients with allergic asthma" 64 : 1728-1736, 2009
• 87 Wang K, "Effects of formoterol-budesonide on airway remodeling in patients with moderate asthma" 32 : 126-132, 2011
• 88 Hothersall EJ, "Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma" 63 : 1070-1075, 2008
• 89 Wegmann M, "Effects of a low-molecularweight CCR-3 antagonist on chronic experimental asthma" 36 : 61-67, 2007
• 90 Castro M, "Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial" 181 : 116-124, 2010
• 91 Wenzel S, "Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies" 370 : 1422-1431, 2007
• 92 Taille C, "ETB receptor polymorphism is associated with airway obstruction" 7 : 5-, 2007
• 93 Aysola R, "Demonstration of the heterogeneous distribution of asthma in the lungs using CT and hyperpolarized helium-3 MRI" 32 : 1379-3187, 2010
• 94 Busse WW, "Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial" 178 : 1002-1008, 2008
• 95 Corren J, "Cytokine inhibition in severe asthma: current knowledge and future directions" 17 : 29-33, 2011
• 96 Coyle AJ, "Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses" 190 : 895-902, 1999
• 97 Wynn TA, "Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases" 117 : 524-529, 2007
• 98 Antony AB, "Cockroach extract antigen increases bronchial airway epithelial permeability" 110 : 589-595, 2002
• 99 Cho JY, "Chronic OVA allergen challenged TNF p55/p75 receptor deficient mice have reduced airway remodeling" 11 : 1038-1044, 2011
• 100 Cho JY, "Chronic OVA allergen challenged Siglec-F deficient mice have increased mucus, remodeling, and epithelial Siglec-F ligands which are up-regulated by IL-4 and IL-13" BIOMED CENTRAL LTD 11 : 2010
• 101 Rabe KF, "Can anti-IgE therapy prevent airway remodeling in allergic asthma" 66 : 1142-1151, 2011
• 102 Charan NB, "Bronchial vascular congestion and angiogenesis" 10 : 1173-1180, 1997
• 103 Cox G, "Bronchial thermoplasty for asthma" 173 : 965-969, 2006
• 104 Trian T, "Bronchial smooth muscle remodeling involves calcium-dependent enhanced mitochondrial biogenesis in asthma" 204 : 3173-3181, 2007
• 105 Nami Shrestha Palikhe, "Biomarkers Predicting Isocyanate-Induced Asthma" 대한천식알레르기학회 3 (3): 21-26, 2011
• 106 Gruenberg D, "Biologic therapies for asthma" 16 : 19-24, 2010
• 107 Redington AE, "Basic fibroblast growth factor in asthma: measurement in bronchoalveolar lavage fluid basally and following allergen challenge" 107 : 384-387, 2001
• 108 Mauad T, "Asthma therapy and airway remod- eling" 120 : 997-1009, 2007
• 109 Cox G, "Asthma control during the year after bronchial thermoplasty" 356 : 1327-1337, 2007
• 110 Van Eerdewegh P, "Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness" 418 : 426-430, 2002
• 111 Song DJ, "Anti-Siglec-F Antibody Reduces Allergen-Induced Eosinophilic Inflammation and Airway Remodeling" AMER ASSOC IMMUNOLOGISTS 183 (183): 5333-5341, 2009
• 112 Flood-Page P, "Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics" 112 : 1029-1036, 2003
• 113 Liu X, "Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma" 386 : 181-185, 2009
• 114 Yum HY, "Allergen-induced coexpression of bFGF and TGF-β1 by macrophages in a mouse model of airway remodeling: bFGF induces macrophage TGF-β1 expression in vitro" 155 : 12-22, 2011
• 115 Chakir J, "Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression" 111 : 1293-1298, 2003
• 116 Girodet PO, "Airway remodeling in asthma: new mechanisms and potential for pharmacological intervention" 130 : 325-337, 2011
• 117 Pascual RM, "Airway remodeling contributes to the progressive loss of lung function in asthma: an overview" 116 : 477-486, 2005
• 118 Kondo Y, "Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system" 20 : 791-800, 2008
• 119 Vandenbroucke RE, "A therapeutic role for MMP inhibitors in lung diseases" 38 : 1200-1214, 2011
• 120 Zhang F, "A soluble thymic stromal lymphopoietin (TSLP) antagonist, TSLPR-immunoglobulin, reduces the severity of allergic disease by regulating pulmonary dendritic cells" 164 : 256-264, 2011
• 121 Al-Shami A, "A role for TSLP in the development of inflammation in an asthma model" 202 : 829-839, 2005
• 122 Wenzel SE, "A randomized, double- blind, placebo-controlled study of tumor necrosis factoralpha blockade in severe persistent asthma" 179 : 549-558, 2009
• 123 Corren J, "A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma" 181 : 788-796, 2010
• 124 Miller JD, "A prospective feasibility study of bronchial thermoplasty in the human airway" 127 : 1999-2006, 2005
• 125 Komai M, "A novel CC-chemokine receptor 3 antagonist, Ki19003, inhibits airway eosinophilia and subepithelial/peribronchial fibrosis induced by repeated antigen challenge in mice" 112 : 203-213, 2010
• 126 Holgate ST, "A new look at the pathogenesis of asthma" 118 : 439-450, 2009
• 127 Humbles AA, "A critical role for eosinophils in allergic airways remodeling" 305 : 1776-1779, 2004
• 128 Abdel-Rahman AM, "A comparative study of two angiogenic factors: vascular endothelial growth factor and angiogenin in induced sputum from asthmatic children in acute attack" 129 : 266-271, 2006
• 129 Fulkerson PC, "A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation" 103 : 16418-16423, 2006